secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001493152-22-031355
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Pharma Q3 2022 revenue $3.2M (+315% YoY); net loss narrows to $3.0M
------------------------------------------------------------------------

- Product sales and royalties $3.2M, up 315% YoY and 37% sequentially, 7th straight sequential growth.
- Net loss $3.0M ($0.12/share) vs $6.1M ($0.24/share) prior year; gross profit $2.0M vs $0.1M.
- ALKINDI SPRINKLE sales grew 183% YoY and 19% QoQ; Carglumic Acid sales up 40% QoQ.
- Acquired Betaine Anhydrous, a third FDA-approved rare disease product, expected accretive in 2023.
- Zonisade FDA approval triggered $5M milestone payment, to be recognized in Q4 2022; cash $13.4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000149315222031355/0001493152-22-031355-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000149315222031355/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-031355

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer